Cover Image

Correlation of Ki67 Expression with Hormone Receptors, Human Epidermal Growth Factor Receptor-2 (HER-2) Status, P53 Mutation and Clinicopathological Characteristics in Pathologic Specimens of Breast Cancer Patients

Seyed Abbas Mirmalek, Maedeh Ghorbani, Ala Gholamrezaei Boushehrinejad, Masoud Salehi, Seyed Alireza Salimi-Tabatabaee, Hoda Aryan
Background: Breast cancer is the main cause of cancer in women and the second cause of ma­lignancy deaths. Ki-67 is one of the molecular markers used to evaluate cancer prognosis along with other factors such as age, tumor size, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), P53, human epidermal growth factor receptor-2 (HER-2), histolog­ical and nuclear grades. This study was aimed to evaluate the correlation of KI-67 expression with some biomarkers and clinico-pathological characteristics in breast cancer patients. Mate­rials and Methods: A total of 513 cases (all female) aged 40- 80 years, were randomly selected from patients who were admitted in two centers affiliated with Tehran University of Medical Sciences (Buo-alli and Kasra hospitals) over a 7-year period (2010-2015). Assessment of tumors for HER-2, P53, ER PR, pathological type and histologic grade was performed. Ki-67 labelling index (Ki-67LI) was defined as the percentage of MIB1-positive cells among a total number of 1,000 malignant cells at high-power magnification (×400). Results: Our study showed that age, ER and PR status were negatively correlated with Ki-67LI (P<0.05). Moreover, number of lymph nodes involved, HER-2, P53 and nuclear grades had a positive correlation with Ki-67LI (P<0.05), whereas, tumor size and histological grade showed no significant correlation with Ki-67LI (P =0.195 and P=0.721, respectively). Conclusion: Results of our study and other studies confirm that the expression of Ki-67 is significantly associated with ER, PR, HER-2 and P53 status. On the other hand, Ki-67 relationship with clinical characteristics such as age, tumor size and lymph node metastasis is not completely established and needs further research.[GMJ.2016;5(2):90-97]
Breast Cancer; Ki-67; Estrogen Receptor; Progesterone Receptor; P53; Human Epidermal Growth Factor Receptor-2

Mirmalek SA, Hajilou M, Salimi Tabatabaee SA, Parsa Y, Yadollah-Damavandi S, Parsa T. Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients. Int J Breast Cancer. 2014; 2014: 564308.

Mirmalek SA, Azizi MA, Jangholi E, Yadollah-Damavandi S, Javidi MA, Parsa Y et al. Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int. 2015; 16: 3.

Mirmalek S, Jangholi E, Jafari M, Yadollah-Damavandi S, Javidi M, Parsa Y et al. Comparison of in Vitro Cytotoxicity and Apoptogenic Activity of Magnesium Chloride and Cisplatin as Conventional Chemotherapeutic Agents in the MCF-7 Cell Line. Asian Pac J Cancer Prev. 2016;17 Spec No.:131-4.

Kogevinas M, Cancer IAfRo. Social inequalities and cancer: International Agency for Research on Cancer Lyon, France; 1997.

Parsa Y, Mirmalek SA, Elham Kani F, Aidun A, Salimi-Tabatabaee SA, Yadollah-Damavandi S, et al. A Review of the Clinical Implications of Breast Cancer Biology. Electronic Physician. 2016; 8(5):2416-24.

Ebrahimi M, Vahdaninia M, Montazeri A. Risk factors for breast cancer in Iran: a case-control study. Breast cancer research. 2002;4(5):R10.

Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in iran, a national study. Iranian Red Crescent medical journal. 2012;14(12):798-804.

Shapochka DO, Zaletok SP, Gnidyuk MI. Relationship between NF-kappaB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Experimental oncology. 2012;34(4):358-63.

Mirmalek SA, Hajilou M, Salimi Tabatabaee SA, Parsa Y, Yadollah-Damavandi S, Parsa T. Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients. Int J Breast Cancer. 2014; 2014: 564308.

Mirmalek SA, Elhamkani F, Tabatabaee SAS, Mahmoodzadeh H, Parsa Y, Yadollah-Damavandi S, et al. Introduction of HER-2 and a Short Review on Its Role in Prognosis and Treatment of Breast Cancer. GMJ. 2014;3(3):132-44.

Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. International journal of cancer Journal international du cancer. 1983;31(1):13-20.

Rahmanzadeh R, Huttmann G, Gerdes J, Scholzen T. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell proliferation. 2007;40(3):422-30.

Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast cancer research : BCR. 2006;8(6):216.

Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry. 1991;12(1):42-9.

Abdsaleh S, Wärnberg F, Azavedo E, Lindgren P, Amini RM. Comparison of core needle biopsy and surgical specimens in malignant breast lesions regarding histological features and hormone receptor expression. Histopathology. 2008;52(6):773-5.

Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki‐67 expression in breast carcinoma. Cancer. 2003;97(5):1321-31.

Weidner N, Moore II DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. Human pathology. 1994;25(4):337-42.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. The Lancet Oncology. 2010;11(2):174-83.

Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Experimental and therapeutic medicine. 2010;1(5):747-54.

de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British journal of cancer. 2007;96(10):1504-13.

Keam B, Im S-A, Lee K-H, Han S-W, Oh D-Y, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast cancer research : BCR. 2011;13(2):R22.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer. 2011;11(1):486.

Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research. 2012;14(1):1-11.

Crispino S, Brenna A, Colombo D, Flores B, D'Amico S, Lissoni P, et al. Ki-67 labeling index in breast cancer. Tumori. 1989;75(6):557-62.

Sahin AA, Ro JY, El‐Naggar AK, Ordonez NG, Ayala AG, Ro J, et al. Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991;68(3):549-57.

Veronese S, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. American journal of clinical pathology. 1991;95(1):30-4.

Midulla C, De Iorio P, Nagar C, Pisani T, Cenci M, Valli C, et al. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer research. 1998;19(5B):4033-7.

Li B, Zhu Z, Wang J, Hou J, Zhao J, Zhang P, et al. [Expression correlation of Ki67 to P53, VEGF, and C-erbB-2 genes in breast cancer and their clinical significances]. Ai zheng= Aizheng= Chinese journal of cancer. 2004;23(10):1176-9.

Payandeh M, Sadeghi M, Fekri A, Sadeghi E. P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran. Journal of Solid Tumors. 2014;4(3):p4.

Golmohammadi R, Pejhan A. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. JPMA The Journal of the Pakistan Medical Association. 2012;62(9):871-5.

Refbacks

  • There are currently no refbacks.